Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The classical HLA-C and the nonclassical HLA-E and HLA-G molecules play important roles both in the innate and adaptive immune system. Starting already during embryogenesis and continuing throughout our lives, these three Ags exert major functions in immune tolerance, defense against infections, and anticancer immune responses. Despite these important roles, identification and characterization of the peptides presented by these molecules has been lacking behind the more abundant HLA-A and HLA-B gene products. In this study, we elucidated the peptide specificities of these HLA molecules using a comprehensive analysis of naturally presented peptides. To that end, the 15 most frequently expressed HLA-C alleles as well as HLA-E*01:01 and HLA-G*01:01 were transfected into lymphoblastoid C1R cells expressing low endogenous HLA. Identification of naturally presented peptides was performed by immunoprecipitation of HLA and subsequent analysis of HLA-bound peptides by liquid chromatographic tandem mass spectrometry. Peptide motifs of HLA-C unveil anchors in position 2 or 3 with high variances between allotypes, and a less variable anchor at the C-terminal end. The previously reported small ligand repertoire of HLA-E was confirmed within our analysis, and we could show that HLA-G combines a large ligand repertoire with distinct features anchoring peptides at positions 3 and 9, supported by an auxiliary anchor in position 1 and preferred residues in positions 2 and 7. The wealth of HLA ligands resulted in prediction matrices for octa-, nona-, and decamers. Matrices were validated in terms of their binding prediction and compared with the latest NetMHC prediction algorithm NetMHCpan-3.0, which demonstrated their predictive power.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“most immunopeptidomic laboratories do not routinely add a cysteine protecting reagent during cell lysis for MHC-IAC.7,8,18,24,27,49,54−57”
From Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome (2021) · cites this paper as [56]
In the citing paper
“Most immunopeptidomic studies either do not consider cysteine modifications18,22,52,54−56 or use cysteinylation as the only cysteine modification allowed in database searches.7,24,27,57”
From Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome (2021) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semi-supervised learning for peptide identification from shotgun proteomics datasets
Käll, L., Canterbury, J. D., Weston, J., Noble, W. S., & MacCoss, M. J. (2007) · Nature Methods · doi:10.1038/nmeth1113 · Cited by 2,424
HLA class I supertypes: a revised and updated classification
Sidney, J., Peters, B., Frahm, N., Brander, C., & Sette, A. (2008) · BMC Immunology · doi:10.1186/1471-2172-9-1 · Cited by 775
Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism
Sette, A., & Sidney, J. (1999) · Immunogenetics · doi:10.1007/s002510050594 · Cited by 635 · cited 1×
“HLA-A and HLA-B alleles: HLA-A*01, -A*02, -A*03, -A*24, -B*07, -B*27, -B*44, -B*58, and -B*62 (57, 58).”
Beyond the increasing complexity of the immunomodulatory HLA-G molecule
Carosella, E. D., Favier, B., Rouas-Freiss, N., Moreau, P., & LeMaoult, J. (2008) · Blood · doi:10.1182/blood-2007-12-127662 · Cited by 348 · cited 1×
“macrophages may also express HLA-G (19).”
Schaefer, M. R., Williams, M., Kulpa, D. A., Blakely, P. K., Yaffee, A. Q., & Collins, K. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.7804 · Cited by 58
Hillen, N., Mester, G., Lemmel, C., Weinzierl, A. O., Müller, M., Wernet, D., Hennenlotter, J., Stenzl, A., Rammensee, H., & Stevanović, S. (2008) · European Journal of Immunology · doi:10.1002/eji.200838632 · Cited by 43
Self-citation
Research works printed but not linked: 85
- Zemmour, 1992, Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C, J. Exp. Med., 176, 937, 10.1084/jem.176.4.937 · DOI · Paper page
- Rech, 2017, T-cell transfer therapy targeting mutant KRAS, N. Engl. J. Med., 376, e11, 10.1056/NEJMc1616637 · DOI · Paper page
- Blais, 2011, HLA-C as a mediator of natural killer and T-cell activation: spectator or key player?, Immunology, 133, 1, 10.1111/j.1365-2567.2011.03422.x · DOI
- Trowsdale, 2008, NK receptor interactions with MHC class I molecules in pregnancy, Semin. Immunol., 20, 317, 10.1016/j.smim.2008.06.002 · DOI
- Falk, 1993, Allele-specific peptide ligand motifs of HLA-C molecules, Proc. Natl. Acad. Sci. USA, 90, 12005, 10.1073/pnas.90.24.12005 · doi:10.1073/pnas.90.24.12005
- Rasmussen, 2014, Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule, J. Immunol., 193, 4790, 10.4049/jimmunol.1401689 · doi:10.4049/jimmunol.1401689
- Braud, 1997, The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9, Eur. J. Immunol., 27, 1164, 10.1002/eji.1830270517 · DOI · Paper page
- Aldrich, 1994, Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen, Cell, 79, 649, 10.1016/0092-8674(94)90550-9 · doi:10.1016/0092-8674(94)90550-9
- Apps, 2015, Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells, J. Immunol., 194, 3594, 10.4049/jimmunol.1403234 · DOI
- Braud, 1998, HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C, Nature, 391, 795, 10.1038/35869 · DOI · Paper page
- Borrego, 2006, The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance, Immunol. Res., 35, 263, 10.1385/IR:35:3:263 · DOI · Paper page
- Malnati, 1995, Peptide specificity in the recognition of MHC class I by natural killer cell clones, Science, 267, 1016, 10.1126/science.7863326 · DOI · Paper page
- Fadda, 2010, Peptide antagonism as a mechanism for NK cell activation, Proc. Natl. Acad. Sci. USA, 107, 10160, 10.1073/pnas.0913745107 · DOI · Paper page
- Borhis, 2013, A peptide antagonist disrupts NK cell inhibitory synapse formation, J. Immunol., 190, 2924, 10.4049/jimmunol.1201032 · doi:10.4049/jimmunol.1201032
- King, 2000, HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells, Eur. J. Immunol., 30, 1623, 10.1002/1521-4141(200006)30:6<1623::AID-IMMU1623>3.0.CO;2-M · doi:10.1002/1521-4141(200006)30:6<1623::aid-immu1623>3.0.co;2-m
- Adams, 2013, The adaptable major histocompatibility complex (MHC) fold: structure and function of nonclassical and MHC class I-like molecules, Annu. Rev. Immunol., 31, 529, 10.1146/annurev-immunol-032712-095912 · DOI · Paper page
- Sullivan, 2006, A structural perspective on MHC class Ib molecules in adaptive immunity, Trends Immunol., 27, 413, 10.1016/j.it.2006.07.006 · DOI
- Curigliano, 2013, Molecular pathways: human leukocyte antigen G (HLA-G), Clin. Cancer Res., 19, 5564, 10.1158/1078-0432.CCR-12-3697 · DOI
- Lin, 2012, HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer, Int. J. Cancer, 131, 150, 10.1002/ijc.26375 · DOI
- Lila, 2000, Implication of HLA-G molecule in heart-graft acceptance, Lancet, 355, 2138, 10.1016/S0140-6736(00)02386-2 · DOI · Paper page
- Colonna, 1997, A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells, J. Exp. Med., 186, 1809, 10.1084/jem.186.11.1809 · DOI · Paper page
- Colonna, 1998, Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules, J. Immunol., 160, 3096, 10.4049/jimmunol.160.7.3096 · DOI · Paper page
- Rajagopalan, 1999, A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. [Published erratum appears in 2000 J. Exp. Med. 191: 1.], J. Exp. Med., 189, 1093, 10.1084/jem.189.7.1093 · DOI · Paper page
- Lee, 1995, The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association, Immunity, 3, 591, 10.1016/1074-7613(95)90130-2 · DOI · Paper page
- Diehl, 1996, Nonclassical HLA-G molecules are classical peptide presenters, Curr. Biol., 6, 305, 10.1016/S0960-9822(02)00481-5 · DOI · Paper page
- Zemmour, 1992, The HLA-A,B “negative” mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon, J. Immunol., 148, 1941, 10.4049/jimmunol.148.6.1941 · doi:10.4049/jimmunol.148.6.1941
- Storkus, 1987, NK susceptibility varies inversely with target cell class I HLA antigen expression, J. Immunol., 138, 1657, 10.4049/jimmunol.138.6.1657 · DOI · Paper page
- Yamada, 1999, Role of anchor residues in peptide binding to three HLA-A26 molecules, Tissue Antigens, 54, 325, 10.1034/j.1399-0039.1999.540401.x · DOI
- Dumrese, 1998, HLA-A26 subtype A pockets accommodate acidic N-termini of ligands, Immunogenetics, 48, 350, 10.1007/s002510050443 · DOI
- Shiga, 1996, Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules, AIDS, 10, 1075
- Kikuchi, 1996, Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket, Immunogenetics, 43, 268, 10.1007/BF02440994 · DOI
- Falk, 1995, Peptide motifs of HLA-B38 and B39 molecules, Immunogenetics, 41, 162, 10.1007/BF00182332 · DOI
- Falk, 1995, Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behćet’s disease, Int. Immunol., 7, 223, 10.1093/intimm/7.2.223 · DOI
- Falk, 1995, Peptide motifs of HLA-B58, B60, B61, and B62 molecules, Immunogenetics, 41, 165, 10.1007/BF00182333 · DOI
- Sidney, 1995, Several HLA alleles share overlapping peptide specificities, J. Immunol., 154, 247, 10.4049/jimmunol.154.1.247 · DOI · Paper page
- Falk, 1994, Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules, Immunogenetics, 40, 238, 10.1007/BF00167086 · DOI
- Abelin, 2017, Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction, Immunity, 46, 315, 10.1016/j.immuni.2017.02.007 · DOI · Paper page
- Andreatta, 2013, Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach, Bioinformatics, 29, 8, 10.1093/bioinformatics/bts621 · DOI
- Rammensee, 1999, SYFPEITHI: database for MHC ligands and peptide motifs, Immunogenetics, 50, 213, 10.1007/s002510050595 · DOI · Paper page
- Nielsen, 2016, NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets, Genome Med., 8, 33, 10.1186/s13073-016-0288-x · DOI · Paper page
- Robinson, 2015, The IPD and IMGT/HLA database: allele variant databases, Nucleic Acids Res., 43, D423, 10.1093/nar/gku1161 · DOI · Paper page
- Barnstable, 1978, Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis, Cell, 14, 9, 10.1016/0092-8674(78)90296-9 · DOI · Paper page
- Falk, 1991, Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules, Nature, 351, 290, 10.1038/351290a0 · DOI · Paper page
- Kowalewski, 2013, Biochemical large-scale identification of MHC class I ligands, Methods Mol. Biol., 960, 145, 10.1007/978-1-62703-218-6_12 · DOI · Paper page
- Eng, 1994, An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database, J. Am. Soc. Mass Spectrom., 5, 976, 10.1016/1044-0305(94)80016-2 · DOI · Paper page
- Steinle, 1996, Motif of HLA-B*3503 peptide ligands, Immunogenetics, 43, 105, 10.1007/BF00186615 · doi:10.1007/bf00186615
- Schittenhelm, 2014, A comprehensive analysis of constitutive naturally processed and presented HLA-C*04:01 (Cw4)-specific peptides, Tissue Antigens, 83, 174, 10.1111/tan.12282 · DOI · Paper page
- Thomsen, 2012, Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion, Nucleic Acids Res., 40, W281, 10.1093/nar/gks469 · DOI · Paper page
- Backert, 2015, Immunoinformatics and epitope prediction in the age of genomic medicine, Genome Med., 7, 119, 10.1186/s13073-015-0245-0 · DOI · Paper page
- Braud, 1998, TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide, Curr. Biol., 8, 1, 10.1016/S0960-9822(98)70014-4 · DOI · Paper page
- Strong, 2003, HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities, J. Biol. Chem., 278, 5082, 10.1074/jbc.M208268200 · DOI · Paper page
- Huyton, 2012, Pocketcheck: updating the HLA class I peptide specificity roadmap, Tissue Antigens, 80, 239, 10.1111/j.1399-0039.2012.01928.x · doi:10.1111/j.1399-0039.2012.01928.x
- del Guercio, 1995, Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype, J. Immunol., 154, 685, 10.4049/jimmunol.154.2.685 · DOI · Paper page
- Doytchinova, 2004, Identifying human MHC supertypes using bioinformatic methods, J. Immunol., 172, 4314, 10.4049/jimmunol.172.7.4314 · DOI · Paper page
- Barth, 2016, Characterization of the canine MHC class I DLA-88*50101 peptide binding motif as a prerequisite for canine T cell immunotherapy, PLoS One, 11, e0167017, 10.1371/journal.pone.0167017 · DOI
- Cheever, 2009, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research, Clin. Cancer Res., 15, 5323, 10.1158/1078-0432.CCR-09-0737 · DOI · Paper page
- Nielsen, 2003, Reliable prediction of T-cell epitopes using neural networks with novel sequence representations, Protein Sci., 12, 1007, 10.1110/ps.0239403 · DOI · Paper page
- Vita, 2015, The immune epitope database (IEDB) 3.0, Nucleic Acids Res., 43, D405, 10.1093/nar/gku938 · DOI · Paper page
- McCutcheon, 1995, Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA, J. Exp. Med., 181, 2085, 10.1084/jem.181.6.2085 · DOI · Paper page
- Neisig, 1998, Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction, J. Immunol., 160, 171, 10.4049/jimmunol.160.1.171 · DOI · Paper page
- Neefjes, 1988, Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association, Eur. J. Immunol., 18, 801, 10.1002/eji.1830180522 · DOI · Paper page
- Setini, 1996, Distinctive features of the alpha 1-domain alpha helix of HLA-C heavy chains free of beta 2-microglobulin, Hum. Immunol., 46, 69, 10.1016/0198-8859(96)00011-0 · DOI
- Mandelboim, 1997, The binding site of NK receptors on HLA-C molecules, Immunity, 6, 341, 10.1016/S1074-7613(00)80336-2 · DOI
- Boyington, 2001, Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules, Immunol. Rev., 181, 66, 10.1034/j.1600-065X.2001.1810105.x · DOI
- Colonna, 1993, HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells, Proc. Natl. Acad. Sci. USA, 90, 12000, 10.1073/pnas.90.24.12000 · DOI · Paper page
- Hilton, 2017, Missing or altered self: human NK cell receptors that recognize HLA-C, Immunogenetics, 69, 567, 10.1007/s00251-017-1001-y · DOI
- Chaux, 1999, Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1, J. Immunol., 163, 2928, 10.4049/jimmunol.163.5.2928 · DOI
- Breckpot, 2004, Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses, J. Immunol., 172, 2232, 10.4049/jimmunol.172.4.2232 · DOI
- Vantomme, 2003, A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16, Cancer Immun., 3, 17
- Heidecker, 2000, Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12, J. Immunol., 164, 6041, 10.4049/jimmunol.164.11.6041 · doi:10.4049/jimmunol.164.11.6041
- Boël, 1995, BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes, Immunity, 2, 167, 10.1016/S1074-7613(95)80053-0 · DOI · Paper page
- Van den Eynde, 1995, A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma, J. Exp. Med., 182, 689, 10.1084/jem.182.3.689 · DOI · Paper page
- Gnjatic, 2000, Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele, Proc. Natl. Acad. Sci. USA, 97, 10917, 10.1073/pnas.97.20.10917 · DOI
- Castelli, 1999, Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens, J. Immunol., 162, 1739, 10.4049/jimmunol.162.3.1739 · doi:10.4049/jimmunol.162.3.1739
- Friedman, 2004, Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate, Eur. J. Immunol., 34, 1091, 10.1002/eji.200324768 · DOI
- Redchenko, 2006, Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4, Immunology, 118, 50, 10.1111/j.1365-2567.2006.02338.x · DOI
- Nagata, 2005, Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient, Clin. Cancer Res., 11, 5265, 10.1158/1078-0432.CCR-04-2542 · DOI
- Tran, 2015, Immunogenicity of somatic mutations in human gastrointestinal cancers, Science, 350, 1387, 10.1126/science.aad1253 · DOI · Paper page
- Chiari, 1999, Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene, Cancer Res., 59, 5785
- Heinzel, 2002, HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells, J. Exp. Med., 196, 1473, 10.1084/jem.20020609 · DOI · Paper page
- Salerno-Gonçalves, 2004, Identification of a human HLA-E-restricted CD8+ T cell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine, J. Immunol., 173, 5852, 10.4049/jimmunol.173.9.5852 · DOI · Paper page
- Romagnani, 2004, HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes, Hum. Immunol., 65, 437, 10.1016/j.humimm.2004.02.001 · DOI
- García, 2002, Human T cell receptor-mediated recognition of HLA-E, Eur. J. Immunol., 32, 936, 10.1002/1521-4141(200204)32:4<936::AID-IMMU936>3.0.CO;2-M · doi:10.1002/1521-4141(200204)32:4<936::aid-immu936>3.0.co;2-m
- Housseau, 1999, Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells, J. Immunol., 163, 6330, 10.4049/jimmunol.163.11.6330 · DOI
- Lampen, 2013, Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2, Mol. Immunol., 53, 126, 10.1016/j.molimm.2012.07.009 · DOI
Cited by
Sarkizova, S., Klaeger, S., Le, P. M., Li, L. W., Oliveira, G., Keshishian, H., Hartigan, C. R., Zhang, W., Braun, D. A., Ligon, K. L., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0322-9 · Cited by 499
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Bulik-Sullivan, B., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F., Yang, A., Young, L., et al. (2019) · Nature Biotechnology · doi:10.1038/nbt.4313 · Cited by 307
Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., Freudenmann, L. K., Backert, L., Mühlenbruch, L., Szolek, A., Lübke, M., Wagner, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002071 · Cited by 250
Self-citationSolleder, M., Guillaume, P., Racle, J., Michaux, J., Pak, H.-S., Müller, M., Coukos, G., Bassani-Sternberg, M., & Gfeller, D. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir119.001641 · Cited by 68
Sturm, T., Sautter, B., Wörner, T. P., Stevanović, S., Rammensee, H.-G., Planz, O., Heck, A. J. R., & Aebersold, R. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00386 · Cited by 63
Self-citation
Metadata
- Authors
- Di Marco, M., Schuster, H., Backert, L., Ghosh, M., Rammensee, H.-G., & Stevanović, S.
- Affiliations
- Department of Immunology, Institute for Cell Biology, University of Tübingen , 72076 Tübingen,
- ORCID
- Ghosh, Michael
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10
- Volume
- 199
- Issue
- 8
- Pages
- 2639-2651
- ISSN
- 0022-1767
- 1550-6606
- Cited by
- 111
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.